Date: 26 November 2013
Biofilms on bronchial epithelial cells in vitro.
Copyright:
Images kindly donated by Frank-Michael C. Müller, Pediatric Pulmonology, Cystic Fibrosis Centre and Infectious Diseases, Department of Pediatrics III, University of Heidelberg, Im Neuenheimer Feld 430, D-69120 Heidelberg, Germany.
Notes:
Confocal scanning laser microscopy (CLSM), using CAAF(green) Fun1(red) stained biofilm. The red color of the FUN 1 cell stain was localized in dense aggregates in the cytoplasm of metabolically active cells. Thus, areas of red fluorescence represented metabolically active cells, and green fluorescence indicated cell wall-like polysaccharides, while yellow areas represented dual staining.
Images library
-
Title
Legend
-
Patient with chronic productive cough, chest pain and ABPA, unable to take itraconazole or nebulised amphotericin B. Smokes at least 40 roll up cigarettes a day.
,
-
Laryngeal aspergillosis, probably related to inhaled corticosteroids.
,
,
,
-
VL-2397 (formerly known as ASP2397) is a novel antifungal drug initially developed by our partner, Astellas Pharma. This drug was isolated from a leaf litter fungus Acremonium species collected in a Malaysian national park. Astellas presented two posters at the 2014 ICAAC meeting which described the in vitro and the in vivo antifungal activities of this drug. The differentiating attributes from the preclinical data of VL-2397 include:
- A novel mechanism of action, with a potential to be complementary or synergistic with the existing classes of antifungals.
- Rapid fungal cell kill activity demonstrated in preclinical models, which was faster than marketed antifungals.
- Activity against azole-resistant fungal species.
- Low propensity for P450 drug-drug interactions.
-
SCY-078, new orally available beta-1,3-d-glucan synthase inhibitor, Formely MK-3118.
-
Pt DSM Community acquired primary Aspergillus pneumonia. Two x-rays taken on 02/02/2010 then 05/03/2010
,